Kura and Kyowa hail phase 2 win for leukemia drug soon heading to FDA, but hold back data
Kura Oncology and Kyowa Kirin claim to have scored a phase 2 win for their oral leukemia treatment while reassuring analysts about the lack of hard data to prove it.
Kura Oncology and Kyowa Kirin claim to have scored a phase 2 win for their oral leukemia treatment while reassuring analysts about the lack of hard data to prove it.
